🌱 Bioplastics Portal

Kaneka Files Patent Infringement Lawsuit Against Teknor Apex and Danimer

Kaneka Corporation Danimer Scientific Teknor Apex PHA PHBH Patent Infringement

Kaneka Corporation has officially filed a patent infringement lawsuit against bioplastic producer Danimer Scientific and custom compounder Teknor Apex. The legal action, filed in early March 2026, centers on proprietary biopolymer technologies and highlights the increasing intellectual property friction within the rapidly expanding polyhydroxyalkanoate (PHA) sector.

The Core of the Dispute

Kaneka, a recognized pioneer in the development of PHBH (poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)), holds a robust portfolio of patents covering the synthesis, processing, and compounding of biodegradable polymers. The Japanese chemical manufacturer alleges that Danimer Scientific, widely known for its Nodax® PHA material, alongside its global compounding partner Teknor Apex, have utilized manufacturing or formulation technologies that infringe upon Kaneka’s protected intellectual property.

Because PHA is synthesized through complex microbiological fermentation rather than traditional chemical catalysis, the proprietary processes and specific blending techniques required to make the raw resin processable on standard manufacturing equipment are highly specialized. As the market for marine-degradable plastics accelerates, protecting these technical formulations has become a critical priority for legacy innovators like Kaneka.

Market Implications for Bioplastics

The inclusion of Teknor Apex in the lawsuit underscores the complexity of the modern bioplastics supply chain. As a major custom compounder, Teknor Apex bridges the critical gap between raw biopolymer producers like Danimer and the end-market converters who manufacture packaging and consumer goods. Danimer and Teknor Apex have previously collaborated to develop custom biodegradable compounds, blending PHA with other materials to achieve the distinct thermal and mechanical properties required for commercial viability.

This litigation could potentially disrupt the supply chain for these specific commercial formulations. As the court proceedings unfold, stakeholders across the bioplastics sector will be closely monitoring the docket. The ultimate resolution may establish significant legal precedents regarding intellectual property boundaries in the compounding and downstream application of next-generation biodegradable polymers.

Source: Read more